Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Content
Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyReported by Chris Markoch. Originally Published: 5/23/2026. 
Key Points
- Kiniksa raised revenue guidance after ARCALYST sales jumped 56% year-over-year.
- The company remains the only FDA-approved treatment provider for recurrent pericarditis.
- Investors are closely watching KPL-387 as a potential next-generation growth catalyst.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Biopharmaceutical stocks require time and patience. But when a company gets it right, investors can be rewarded, as they have been with Kiniksa Pharmaceuticals (NASDAQ: KNSA). The stock is up more than 100% over the last year. Much of that gain came after the company’s strong Q1 earnings report on April 28, when it topped adjusted earnings per share (EPS) estimates by 9 cents, coming in at 27 cents. At that time, the company also announced the launch of a targeted direct-to-consumer TV campaign for ARCALYST in recurrent pericarditis. ARCALYST is the first and only U.S. Food & Drug Administration (FDA) approved therapy for recurrent pericarditis, a designation it received in 2021.
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid
After some initial volatility, ARCALYST generated about $48 million in revenue in March 2023. Revenue growth has since accelerated, reaching a new record of $214.27 million in Q1 2026, a 56% year-over-year (YOY) increase. The new campaign is significant because it shows that Kiniksa is investing in demand generation at scale rather than relying solely on prescriber growth. To that end, the company raised its full-year revenue guidance to $930 million to $945 million. Prior guidance called for a range between $900 million and $920 million. A Singular Focus Moving Into Its Second GenerationLike many biotech companies, Kiniksa focuses on discovering and advancing novel, transformative therapies for patients with unmet medical needs. The company’s specific focus is on cardiovascular diseases, especially pericarditis. Pericarditis is an inflammation of the pericardium—the thin, fluid-filled sac surrounding the heart—that causes sharp chest pain, fatigue and, in severe cases, dangerous fluid buildup around the heart. When the condition keeps coming back despite standard anti-inflammatory treatments like NSAIDs and colchicine, it becomes recurrent pericarditis, a chronic autoinflammatory disease driven by an overactive IL-1 immune response. How big is this market? Approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year, with roughly 14,000 of those experiencing two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies. That 14,000 is roughly equal to Kiniksa’s initial target market, of which 18% were on ARCALYST by the end of 2025. That leaves about 80% of the addressable market untreated, and for now, Kiniksa has the field to itself. It is moving quickly to keep competitors out. That leads to the company’s pipeline, which includes its KPL-387 drug. This is a once-monthly subcutaneous self-injection that marks a significant upgrade over ARCALYST’s more frequent dosing. KPL-387, which is in Phase 2 trials, received FDA Orphan Drug Designation (ODD) in October 2025. Among the many benefits of ODD is that Kiniksa will have exclusive marketing rights for seven years. Investors in the biotech space value exclusivity, and this gives Kiniksa another opportunity to deliver. Valuation May Become a ConcernBiotechnology stocks can be volatile, and Kiniksa is no different. However, unlike many speculative biotech names that are unprofitable and have little to no revenue, Kiniksa has become a profitable company with revenue that is growing sequentially and YOY. That said, KNSA now trades at around 60x earnings. That’s a significant premium to the S&P 500 (around 27x) and the broader biotech sector (around 17x). The bull case is that Kiniksa has earned this premium with an outlook for strong revenue growth and higher margins. Skeptics could counter that the current stock price depends on flawless execution, which may or may not happen. However, waiting on the sidelines has not worked out well for investors, and the consensus price target of $60.86 still leaves healthy upside from current levels. KNSA Chart Makes an Argument to WaitThe technical picture supports a measured approach for investors considering a position. After surging nearly 20% after the earnings report, KNSA has pulled back to the $53-$54 range on declining volume. This signals a healthy consolidation, not a structural breakdown. The relative strength index (RSI) has retreated from overbought territory near 80 to a neutral 51, indicating that the post-earnings momentum excess has been worked off without significant price damage. The MACD crossover, however, suggests modest near-term selling pressure may not be fully exhausted. 
Investors looking for a more defined entry point may want to watch the 50-day simple moving average, currently in the $47-$49 range. A successful test of that level—particularly if the MACD turns positive on the retest—would confirm that the broader uptrend remains intact and could offer a more favorable risk-reward setup ahead of the anticipated KPL-387 Phase 2 data in the second half of 2026. |
Post a Comment
Post a Comment